WMJ-S-001, a novel aliphatic hydroxamate derivative, exhibits anti-angiogenic activities via Src-homology-2-domaincontaining protein tyrosine phosphatase 1

Yi Fang Chang, Ya Fen Hsu, Pei Ting Chiu, Wei Jan Huang, Shiu Wen Huang, George Ou, Joen Rong Sheu, Ming Jen Hsu

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Angiogenesis, one of the major routes for tumor invasion and metastasis represents a rational target for therapeutic intervention. Recent development in drug discovery has highlighted the diverse biological and pharmacological properties of hydroxamate derivatives. In this study, we characterized the anti-angiogenic activities of a novel aliphatic hydroxamate, WMJ-S-001, in an effort to develop novel angiogenesis inhibitors. WMJ-S-001 inhibited vascular endothelial growth factor (VEGF)-A-induced proliferation, invasion and endothelial tube formation of human umbilical endothelial cells (HUVECs). WMJ-S-001 suppressed VEGF-A-induced microvessel sprouting from aortic rings, and attenuated angiogenesis in in vivo mouse xenograft models. In addition, WMJ-S-001 inhibited the phosphorylations of VEGFR2, Src, FAK, Akt and ERK in VEGF-A-stimulated HUVECs. WMJ-S-001 caused an increase in SHP-1 phosphatase activity, whereas NSC-87877, a SHP-1 inhibitor, restored WMJ-S-001 suppression of VEGFR2 phosphorylation and cell proliferation. Furthermore, WMJ-S-001 inhibited cell cycle progression and induced cell apoptosis in HUVECs. These results are associated with p53 phosphorylation and acetylation and the modulation of p21 and survivin. Taken together, WMJ-S-001 was shown to modulate vascular endothelial cell remodeling through inhibiting VEGFR2 signaling and induction of apoptosis. These results also support the role of WMJ-S-001 as a potential drug candidate and warrant the clinical development in the treatment of cancer.

Original languageEnglish
Pages (from-to)85-100
Number of pages16
JournalOncotarget
Volume6
Issue number1
Publication statusPublished - 2015

Fingerprint

Protein Phosphatase 1
Protein Tyrosine Phosphatases
Vascular Endothelial Growth Factor A
Phosphorylation
NSC-87877
Endothelial Cells
Non-Receptor Type 6 Protein Tyrosine Phosphatase
Apoptosis
Umbilicus
WMJ-S-001
Angiogenesis Inhibitors
Drug Discovery
Acetylation
Microvessels
Heterografts
Neoplasms
Cell Cycle
Cell Proliferation
Pharmacology
Neoplasm Metastasis

Keywords

  • Angiogenesis
  • Endothelial cells
  • Hydroxamate
  • p53
  • VEGF

ASJC Scopus subject areas

  • Oncology

Cite this

@article{345d1d85e19b45c0afff5c07759e6bb6,
title = "WMJ-S-001, a novel aliphatic hydroxamate derivative, exhibits anti-angiogenic activities via Src-homology-2-domaincontaining protein tyrosine phosphatase 1",
abstract = "Angiogenesis, one of the major routes for tumor invasion and metastasis represents a rational target for therapeutic intervention. Recent development in drug discovery has highlighted the diverse biological and pharmacological properties of hydroxamate derivatives. In this study, we characterized the anti-angiogenic activities of a novel aliphatic hydroxamate, WMJ-S-001, in an effort to develop novel angiogenesis inhibitors. WMJ-S-001 inhibited vascular endothelial growth factor (VEGF)-A-induced proliferation, invasion and endothelial tube formation of human umbilical endothelial cells (HUVECs). WMJ-S-001 suppressed VEGF-A-induced microvessel sprouting from aortic rings, and attenuated angiogenesis in in vivo mouse xenograft models. In addition, WMJ-S-001 inhibited the phosphorylations of VEGFR2, Src, FAK, Akt and ERK in VEGF-A-stimulated HUVECs. WMJ-S-001 caused an increase in SHP-1 phosphatase activity, whereas NSC-87877, a SHP-1 inhibitor, restored WMJ-S-001 suppression of VEGFR2 phosphorylation and cell proliferation. Furthermore, WMJ-S-001 inhibited cell cycle progression and induced cell apoptosis in HUVECs. These results are associated with p53 phosphorylation and acetylation and the modulation of p21 and survivin. Taken together, WMJ-S-001 was shown to modulate vascular endothelial cell remodeling through inhibiting VEGFR2 signaling and induction of apoptosis. These results also support the role of WMJ-S-001 as a potential drug candidate and warrant the clinical development in the treatment of cancer.",
keywords = "Angiogenesis, Endothelial cells, Hydroxamate, p53, VEGF",
author = "Chang, {Yi Fang} and Hsu, {Ya Fen} and Chiu, {Pei Ting} and Huang, {Wei Jan} and Huang, {Shiu Wen} and George Ou and Sheu, {Joen Rong} and Hsu, {Ming Jen}",
year = "2015",
language = "English",
volume = "6",
pages = "85--100",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "1",

}

TY - JOUR

T1 - WMJ-S-001, a novel aliphatic hydroxamate derivative, exhibits anti-angiogenic activities via Src-homology-2-domaincontaining protein tyrosine phosphatase 1

AU - Chang, Yi Fang

AU - Hsu, Ya Fen

AU - Chiu, Pei Ting

AU - Huang, Wei Jan

AU - Huang, Shiu Wen

AU - Ou, George

AU - Sheu, Joen Rong

AU - Hsu, Ming Jen

PY - 2015

Y1 - 2015

N2 - Angiogenesis, one of the major routes for tumor invasion and metastasis represents a rational target for therapeutic intervention. Recent development in drug discovery has highlighted the diverse biological and pharmacological properties of hydroxamate derivatives. In this study, we characterized the anti-angiogenic activities of a novel aliphatic hydroxamate, WMJ-S-001, in an effort to develop novel angiogenesis inhibitors. WMJ-S-001 inhibited vascular endothelial growth factor (VEGF)-A-induced proliferation, invasion and endothelial tube formation of human umbilical endothelial cells (HUVECs). WMJ-S-001 suppressed VEGF-A-induced microvessel sprouting from aortic rings, and attenuated angiogenesis in in vivo mouse xenograft models. In addition, WMJ-S-001 inhibited the phosphorylations of VEGFR2, Src, FAK, Akt and ERK in VEGF-A-stimulated HUVECs. WMJ-S-001 caused an increase in SHP-1 phosphatase activity, whereas NSC-87877, a SHP-1 inhibitor, restored WMJ-S-001 suppression of VEGFR2 phosphorylation and cell proliferation. Furthermore, WMJ-S-001 inhibited cell cycle progression and induced cell apoptosis in HUVECs. These results are associated with p53 phosphorylation and acetylation and the modulation of p21 and survivin. Taken together, WMJ-S-001 was shown to modulate vascular endothelial cell remodeling through inhibiting VEGFR2 signaling and induction of apoptosis. These results also support the role of WMJ-S-001 as a potential drug candidate and warrant the clinical development in the treatment of cancer.

AB - Angiogenesis, one of the major routes for tumor invasion and metastasis represents a rational target for therapeutic intervention. Recent development in drug discovery has highlighted the diverse biological and pharmacological properties of hydroxamate derivatives. In this study, we characterized the anti-angiogenic activities of a novel aliphatic hydroxamate, WMJ-S-001, in an effort to develop novel angiogenesis inhibitors. WMJ-S-001 inhibited vascular endothelial growth factor (VEGF)-A-induced proliferation, invasion and endothelial tube formation of human umbilical endothelial cells (HUVECs). WMJ-S-001 suppressed VEGF-A-induced microvessel sprouting from aortic rings, and attenuated angiogenesis in in vivo mouse xenograft models. In addition, WMJ-S-001 inhibited the phosphorylations of VEGFR2, Src, FAK, Akt and ERK in VEGF-A-stimulated HUVECs. WMJ-S-001 caused an increase in SHP-1 phosphatase activity, whereas NSC-87877, a SHP-1 inhibitor, restored WMJ-S-001 suppression of VEGFR2 phosphorylation and cell proliferation. Furthermore, WMJ-S-001 inhibited cell cycle progression and induced cell apoptosis in HUVECs. These results are associated with p53 phosphorylation and acetylation and the modulation of p21 and survivin. Taken together, WMJ-S-001 was shown to modulate vascular endothelial cell remodeling through inhibiting VEGFR2 signaling and induction of apoptosis. These results also support the role of WMJ-S-001 as a potential drug candidate and warrant the clinical development in the treatment of cancer.

KW - Angiogenesis

KW - Endothelial cells

KW - Hydroxamate

KW - p53

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=84921383676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921383676&partnerID=8YFLogxK

M3 - Article

C2 - 25415226

AN - SCOPUS:84921383676

VL - 6

SP - 85

EP - 100

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 1

ER -